The clinical picture includes short stature, multiple endocrine abnormalities (hypogonadism, growth hormone/insulin-like growth factor-I axis dysfunction, hypothyroidism, central adrenal insufficiency), dysmorphic features, scoliosis, osteoporosis, mental retardation, and behavioral and psychiatric problems
Researchers who have encountered questions about timing, metabolic interactions, or the persistence of peptide effects in research models may find useful parallel context in our article on how long peptide-related effects last in GLP-1 receptor agonist research
These symptoms are uncommon but warrant professional assessment to exclude complications or the need for medication adjustment
SureNanos interest in formulation and delivery technologies within these emerging areas aligns with the companys broader emphasis on drug-delivery innovation and platform flexibility
Inject during the fasting window, not during the eating window
Pregnancy and breastfeeding